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Perspectives
L
inguistically speaking, the 
predominant viral cause 
of gastroenteritis has been 
evolving. Once evocatively called winter
vomiting disease, the pathogen’s name 
has changed alongside improved 
scientiﬁc understanding. First called 
Norwalk virus (or Norwalk-like virus) 
in reference to the Ohio town where 
specimens from a school outbreak 
enabled the seminal work that ﬁrst 
characterised the virus, it was later 
dubbed the Small Round Structured 
Virus following visualisation by 
electron microscopy. The International 
Committee on Taxonomy of Viruses 
later settled on the present name of 
“norovirus”, classifying it as a member 
of the Caliciviridae family based on 
both morphology and phylogeny. 
A new study published in this issue 
of PLoS Medicine suggests that the 
colloquial “gastric ﬂu” may have been 
the most apt term of all [1]. When 
media reports call “norovirus” just “a 
fancy word for gastric ﬂu”, they allude 
to similar seasonality and the lack of 
effective therapeutics for inﬂuenza 
and norovirus, but the analogy may 
run deeper [2]. There are parallels 
with respect to inﬂuenza and norovirus 
evolution and human immunity.
In the new study, Ralph Baric and 
colleagues present compelling data to 
demonstrate that norovirus evolution is 
driven by immune selection pressure. 
The domain of the exposed viral capsid 
protein that binds carbohydrates in the 
human gut evolves in the face of herd 
immunity. Histoblood group antigens 
(HBGAs), a heterogeneous group 
of related carbohydrates on mucosal 
surfaces, provide a “docking station” 
for noroviruses, and there is a large 
variety of such HBGAs. These sites are 
similar, but distinct, so as the capsid 
mutates and subtly changes its shape, 
it can still ﬁnd new binding sites on 
the mucosal surface of the gut. The 
virus survives despite the build-up of 
immunity in the population because 
there is room in antigenic space for the 
virus to evolve and remain infectious. 
As with inﬂuenza, the predominant 
circulating norovirus may also change 
its antigenicity frequently, giving it 
the potential to cause pandemics and 
necessitate regular reformulation of 
vaccine.
Norovirus Epidemiology
Noroviruses are the most commonly 
detected pathogen both in sporadic 
cases and outbreaks of gastroenteritis. 
They are particularly problematic in 
environments where groups congregate 
and infection can be rapidly 
transmitted through both faecal and 
vomitus routes. Outbreaks affect health 
care facilities worldwide, and may 
cause massive disruption to providing 
care, substantial economic loss, and, 
according to some reports, mortality in 
vulnerable patient populations [3–5]. 
As is typical of positive-sense single-
stranded RNA viruses, noroviruses 
are diverse. There are two main 
genogroups affecting humans and 
approximately 15 genotypes within 
these groups, with substantial genetic 
heterogeneity between genogroups 
(60% divergence in the ORF2 major 
capsid protein) and genotypes within a 
genogroup (approximately 20%–30% 
divergence). At least since 1995 a single 
type—genotype II.4—has been the 
predominant circulating virus. 
Noroviruses’ Escape from 
Population Immunity?
Some individuals, upon being 
challenged with norovirus infection, 
develop gastroenteritis, while others 
develop asymptomatic infection and 
some show no signs of infection at 
all. This points to a role of acquired 
immunity as well as innate resistance 
to infection. Indeed, individuals 
who genetically encode the enzyme 
FUT2 α-fucosyltransferase and are 
secretor-positive (i.e., they express 
HBGAs) are susceptible to Norwalk 
virus (a GI.1 virus) infection. Distinct 
binding patterns have been described 
for a range of other GI and GII 
strains, including GII.4. Acquired 
immunity is not thought to last until a 
subsequent norovirus season, though 
a few individuals may acquire longer-
lasting immunity. With these factors 
combined, one might think that 
immune selection pressure would be 
rather transient—only heavy at the end 
of a season—and that an evolutionarily 
stable strategy for norovirus might be 
to wait out the summer low season and 
attack again when population immunity 
has waned. This is not what Baric and 
colleagues have found.
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Linked Research Article
This Perspective discusses the 
following new study published in PLoS
Medicine:
Lindesmith LC, Donaldson EF, 
LoBue AD, Cannon JL, Zheng DP, et al. 
(2008) Mechanisms of GII.4 norovirus 
persistence in human populations. 
PLoS Med 5(2): e31. doi:10.1371/journal.
pmed.0050031
Through phylogenetic analysis of 
norovirus isolates, Ralph Baric and 
colleagues show that new epidemic 
strains arise as the variety of available 
cellular receptors permits antigenic drift 
in the viral capsid.PLoS Medicine  |  www.plosmedicine.org 0188 February 2008  |  Volume 5  |  Issue 2  |  e42
Findings of the New Study
Instead, their ﬁndings suggest (1) that 
noroviruses are under heavy selective 
pressure and (2) that the norovirus 
capsid, which contains both antigenic 
sites and carbohydrate binding ligands, 
seems to have been ﬁnely tuned to 
evolve. The P2 region of the capsid 
is attached to the virus shell by a 
ﬂexible hinge, so—with minor genetic 
tweaking—the virus can nuzzle up to 
a range of HBGA sites. This domain is 
evolving at a faster rate than regions 
not coding for surface residues. 
But perhaps Baric’s most compelling 
evidence that the virus evolves in the 
face of human immunity comes in the 
form of serology (since noroviruses 
can’t be grown in cell culture, blocking 
assays are used as an alternative to 
neutralising antibody experiments). 
Pre-epidemic anti-serum binds poorly 
to post-epidemic virus-like particles; 
this observation was most extreme 
for the 2002–2003 epidemic, which 
by many accounts [6,7] was the most 
severe epidemic recorded. That year’s 
strain appears to have had a novel 
surface antigen, effectively leaving the 
whole population susceptible. Once 
again, as with inﬂuenza, it appears 
that noroviruses may undergo genetic 
drift, punctuated by a shift every three 
years or so. The trade-off between 
replication ﬁtness and evasion of the 
immune response may underlie the 
so-called “epochal shifts”. Interestingly, 
these shifts seem to be occurring more 
frequently now, with epidemic variants 
identiﬁed in 2002, 2004, and 2005. 
This 2007–2008 winter may have been 
epidemic in the United Kingdom, 
where extensive hospital ward 
outbreaks occurred [8], and perhaps 
in other countries as well. Could it be 
that norovirus has pushed itself into 
an evolutionary corner: having caused 
widespread infection, and therefore 
higher levels of population immunity, 
might it need to evolve faster to persist? 
There are, however, important 
differences between inﬂuenza and 
norovirus evolution and epidemiology. 
Although GII.4 viruses predominate, 
they do so within a large population of 
co-circulating genotypes. In contrast, 
a new inﬂuenza subtype generally 
replaces existing types. Following 
antigenic shift, replaced inﬂuenza 
types tend to go extinct, while usurped 
norovirus variants continue to circulate 
at low levels. Such differences are 
probably driven by the short-lived 
non-sterilising immunity to norovirus 
compared with the longer-term 
protection to inﬂuenza antigens. 
Indeed, the other norovirus genotypes 
may well be operating under different 
selective pressure than GII.4.
What Next?
Baric and colleagues’ landmark paper 
sets forth a wide research agenda for 
norovirus vaccinology, virology, and 
epidemiology. The authors are bullish 
that their ﬁndings take us towards the 
development of norovirus vaccines. 
This is undoubtedly true—though it is 
unlikely that a major pharmaceutical 
company will invest the massive sums 
required to bring to market a product 
for such an antigenically diverse virus 
that confers short-lived immunity and 
is perceived to cause a relatively low 
burden of disease. We think this lack 
of investment in developing a vaccine 
would be unfortunate; vaccination 
targeted at vulnerable populations and 
health care workers could mitigate 
the most severe health and economic 
consequences caused by noroviruses. 
Formulation of a norovirus vaccine 
would be challenging, but tools 
developed for understanding inﬂuenza 
evolution could prove useful. For 
example, data generated from Baric 
and colleagues’ serological experiments 
lend themselves to fascinating antigenic 
mapping methods used to quantify and 
visualise antigenic differences between 
circulating inﬂuenza strains [9], and 
may prove effective in predicting 
norovirus evolution. 
What is really needed—but has been 
lacking—is a good in vitro cell culture 
system. Such a system would facilitate 
investigation of the relationship 
between antigen and receptor and 
how antibody interferes with binding. 
The ﬁnding that secretor-negative 
individuals are still susceptible to 
infection suggests that the HBGAs are 
only one link in a binding hierarchy.
An area absent from Baric and 
colleagues’ paper is a discussion of 
the seasonality of norovirus. Like 
inﬂuenza, noroviruses exhibit a 
strong wintertime seasonality (see 
Figure 1 and [10] for a discussion 
of ﬂu seasonality), and new variants 
disseminate rapidly. But unlike 
ﬂu, noroviruses do not disappear 
during summer, nor do they have 
animal hosts acting as a reservoir 
for frequent re-introductions. The 
environmental and host behavioural 
factors that may inﬂuence norovirus 
seasonality are not understood. But 
such factors are likely to interact 
with herd immunity in a complex 
way. For example, environmental 
factors (such as lower temperature 
and diminished ultraviolet light) 
may increase the virus’ transmission 
potential, exacerbated by high winter-
time hospital occupancy; this in turn 
may trigger a seasonal epidemic, which 
results in high levels of population 
immunity. At the springtime end of 
the season, population immunity, and 
doi:10.1371/journal.pmed.0050042.g001
Figure 1. Laboratory Reports of Norovirus-Positive Specimens in England and Wales, 1991 to 
2006
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hence selective pressure, would be at 
its highest. Indeed, it is in the warmer 
months that new epidemic variants 
often emerge. Baric and colleagues’ 
article arrives at the height of the 
norovirus season. But as spring comes 
and the annual epidemic wanes, we 
should remain vigilant. It is then that 
the next pandemic strain is likely to 
emerge.  
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